The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it.
Eleusis’ IV form of psilocin will see clinical trials, but Eleusis-backed research into the anti-inflammatory properties of psychedelics is uncertain.
The acquisition is the latest sign of stress among startups in the sector, which has seen valuations plummet.
With the support of his family, Cody Swift has funded pivotal research into psychedelic therapies and the conservation of peyote and other Indigenous medicines.
The company is betting that psychedelic medicines can promote physical as well as mental health. Can it convince investors?
An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.
Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”
Porta Sophia is building an online database of prior art pertaining to psychedelics with the goal of improving the flawed psychedelic patent process.
Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.
Mimosa Therapeutics has created a cultured psilocybin mycelium product called Pearls that can be precisely dosed like synthetic psilocybin, but contains all the mushroom’s compounds.